ECTRIMS eLearning

MOG-antibody- related disorders cohort description: common features and ucommon presentations
Author(s): ,
A Cobo-Calvo
Affiliations:
Département de Neurologie, Hôpital Pierre Wertheimer, Hospices Civils de Lyon, Lyon er;Lyon's Neuroscience Research Center, Team ONCOFLAM, INSERM U 2 / CNRS , Lyon
,
A Ruiz
Affiliations:
Lyon's Neuroscience Research Center, Team ONCOFLAM, INSERM U 2 / CNRS , Lyon
,
A.-L Poulat
Affiliations:
Department Neurologie pédiatrique, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France
,
M Carneiro
Affiliations:
Department Neurologie pédiatrique, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France
,
F Durand-Dubief
Affiliations:
Département de Neurologie, Hôpital Pierre Wertheimer, Hospices Civils de Lyon, Lyon er
,
S Vukusic
Affiliations:
Département de Neurologie, Hôpital Pierre Wertheimer, Hospices Civils de Lyon, Lyon er
,
V Desportes
Affiliations:
Department Neurologie pédiatrique, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France
R Marignier
Affiliations:
Département de Neurologie, Hôpital Pierre Wertheimer, Hospices Civils de Lyon, Lyon er;Lyon's Neuroscience Research Center, Team ONCOFLAM, INSERM U 2 / CNRS , Lyon
ECTRIMS Learn. Cobo- Calvo A. 09/16/16; 146649; P809
Alvaro Cobo- Calvo
Alvaro Cobo- Calvo
Contributions
Abstract

Abstract: P809

Type: Poster

Abstract Category: Clinical aspects of MS - MS Variants

Introduction: Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) have been recently reported mainly in acute demyelinating encephalomyelitis (ADEM) and optic neuritis (ON) in children and Neuromyelitis Optica spectrum disorders (NMOSD) in adults. Since MOG-Ab related disorders are an emerging entity, the whole spectrum has likely not been completely described.

Objectives: To delineate clinical, laboratory and radiological features in a cohort of MOG-Ab positive patients.

Methods: Twenty four consecutive paediatric (≤16 years old) and adult patients testing positive for MOG-Ab between January 2014 through April 2016 were included. Comprehensive epidemiological, clinical, laboratory and magnetic resonance imaging (MRI) were retrospectively analyzed.

Results: Among the whole cohort, 12 (50%) were paediatric and 50% were men. MOG-Ab related disorders comprised 9 ADEM, 4 NMOSD, 5 monophasic acute myelitis (4 extensive and 1 non-extensive), 5 ON (1 monophasic and 4 relapsing) and one multiple sclerosis (MS). After a median follow-up of 14.83 months (interquartile range, 7.6-69.2), 10 (41.7%) patients presented a relapsing course. Among those with an abnormal brain MRI, 6 (40%) showed specific bilateral thalamic lesions and 5 (33%) in the fourth ventricle (increasing to 71.4% and 50% among the paediatric cohort, respectively). There were no differences between paediatrics and adults patients regarding gender, relapsing course, radiological features or outcome apart of a tendency for encephalopathy as a first clinical presentation in the paediatric group (50% vs 8.1%, respectively p=0.069). We identified unusual presentation in 5 patients: an associated teratoma (n=1), a concomitant HHV-6 myelitis (n=1), an associated neurofribromatosis-1 (n=1), seizures (n=1), and a non-extensive myelitis showing a “patchy pattern” along the whole spinal cord MRI (n=1).

Conclusion: MOG-Ab related disorders shared common clinical and prognostic features but encompasses a spectrum much wider than recently reported.

Disclosure: Cobo-Calvo A: Nothing to disclose

Ruiz A: Nothing to disclose

Anne-Lise P: Nothing to disclose

Marilyne C:Nothing to disclose

Durand-Dubief F: Nothing to disclose

Vukusic S:Nothing to disclose

Desportes V: Nothing to disclose

Marignier R: Nothing to disclose

Abstract: P809

Type: Poster

Abstract Category: Clinical aspects of MS - MS Variants

Introduction: Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) have been recently reported mainly in acute demyelinating encephalomyelitis (ADEM) and optic neuritis (ON) in children and Neuromyelitis Optica spectrum disorders (NMOSD) in adults. Since MOG-Ab related disorders are an emerging entity, the whole spectrum has likely not been completely described.

Objectives: To delineate clinical, laboratory and radiological features in a cohort of MOG-Ab positive patients.

Methods: Twenty four consecutive paediatric (≤16 years old) and adult patients testing positive for MOG-Ab between January 2014 through April 2016 were included. Comprehensive epidemiological, clinical, laboratory and magnetic resonance imaging (MRI) were retrospectively analyzed.

Results: Among the whole cohort, 12 (50%) were paediatric and 50% were men. MOG-Ab related disorders comprised 9 ADEM, 4 NMOSD, 5 monophasic acute myelitis (4 extensive and 1 non-extensive), 5 ON (1 monophasic and 4 relapsing) and one multiple sclerosis (MS). After a median follow-up of 14.83 months (interquartile range, 7.6-69.2), 10 (41.7%) patients presented a relapsing course. Among those with an abnormal brain MRI, 6 (40%) showed specific bilateral thalamic lesions and 5 (33%) in the fourth ventricle (increasing to 71.4% and 50% among the paediatric cohort, respectively). There were no differences between paediatrics and adults patients regarding gender, relapsing course, radiological features or outcome apart of a tendency for encephalopathy as a first clinical presentation in the paediatric group (50% vs 8.1%, respectively p=0.069). We identified unusual presentation in 5 patients: an associated teratoma (n=1), a concomitant HHV-6 myelitis (n=1), an associated neurofribromatosis-1 (n=1), seizures (n=1), and a non-extensive myelitis showing a “patchy pattern” along the whole spinal cord MRI (n=1).

Conclusion: MOG-Ab related disorders shared common clinical and prognostic features but encompasses a spectrum much wider than recently reported.

Disclosure: Cobo-Calvo A: Nothing to disclose

Ruiz A: Nothing to disclose

Anne-Lise P: Nothing to disclose

Marilyne C:Nothing to disclose

Durand-Dubief F: Nothing to disclose

Vukusic S:Nothing to disclose

Desportes V: Nothing to disclose

Marignier R: Nothing to disclose

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies